Late-onset NPM1 mutation in a MYC-amplified relapsed/refractory acute myeloid leukemia patient treated with gemtuzumab ozogamicin and glasdegib

Haematologica. 2024 Nov 1;109(11):3811-3815. doi: 10.3324/haematol.2023.284922.
No abstract available

Grants and funding

Funding: This research was funded by the José Carreras Leukaemia Foundation (DJCLS 01SP/(12)2022). CP is supported by a Max-Eder grant of German Cancer Aid (70114435). The authors gratefully acknowledge the data storage service SDS@hd supported by the Ministry of Science, Research and the Arts Baden-Württemberg (MWK) and the German Research Foundation (DFG) through grant INST 35/1314-1 FUGG and INST 35/1503-1 FUGG. MS was supported through the Walter Benjamin Fellowship funded by Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – 493935791.